Breathe Well Live Well
|
Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at …
News-Medical.net Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be … |
View full post on asthma – Google News
|
Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled …
MarketWatch (press release) "We are strongly committed to advancing a pipeline of iCALM therapies to treat chronic respiratory diseases, including COPD, asthma and cystic fibrosis." "iCALM's ability to limit allergen-induced eosinophilic airway inflammation in this trial is … |
View full post on asthma – Google News